Welcome to our dedicated page for Annovis Bio SEC filings (Ticker: ANVS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Annovis Bio, Inc. (ANVS) SEC filings page provides access to the company’s official regulatory documents as filed with the U.S. Securities and Exchange Commission. Annovis is a late-stage clinical drug platform company focused on neurodegenerative diseases such as Alzheimer’s disease and Parkinson’s disease, and its filings offer detailed insight into its clinical programs, financial condition, capital structure, and governance.
Through periodic reports and current reports on Form 8‑K, Annovis discloses material events such as registered direct offerings of common stock and pre‑funded warrants under its Form S‑3 shelf registration statement, the intended use of proceeds for the continued clinical development of buntanetap and general corporate purposes, and engagement terms with placement agents. Other 8‑K filings describe leadership changes, including appointments and resignations in finance roles, annual meeting voting results, and matters such as NYSE listing compliance plan acceptance.
Investors following Annovis’ late-stage clinical activities can also use SEC filings to connect financial updates with the company’s development plans. Earnings-related 8‑K filings furnish press releases that summarize research and development expenses, general and administrative costs, and net loss figures for specified reporting periods, alongside narrative corporate updates on the pivotal Phase 3 Alzheimer’s trial and other clinical milestones.
On this page, users can review real-time updates as new filings appear on EDGAR, including future annual reports on Form 10‑K, quarterly reports on Form 10‑Q, and additional 8‑K disclosures. AI-powered tools on the platform can help summarize lengthy documents, highlight key sections on topics such as financing terms, clinical development priorities, or listing status, and make it easier to navigate complex language. For those analyzing ANVS, this filings archive is a primary source for understanding how Annovis reports its progress, risks, and obligations in connection with the development of buntanetap and its broader corporate activities.
Annovis Bio reported a cash balance of $17.1 million as of June 30, 2025 and a six-month net loss of $11.8 million, leaving an accumulated deficit of $146.6 million. Operating loss for the six months was $12.6 million versus $15.6 million in the prior year period. Net proceeds of $19.3 million were generated from a February 2025 underwritten offering with ThinkEquity, and the company sold an additional $0.5 million of common stock under its December 2024 ATM during the six months.
The filing discloses that management has concluded substantial doubt exists about the company’s ability to continue as a going concern and is pursuing additional capital through equity or debt financings, collaborations or cost deferrals. On the clinical front, Annovis initiated its FDA-cleared pivotal ANVS-25001 Phase 3 trial in early Alzheimer’s disease in February 2025 and describes prior topline PD and AD data and alignment with the FDA on a development path for buntanetap.
Annovis Bio, Inc. furnished a Current Report on Form 8-K stating that on August 12, 2025 the company issued a press release announcing its financial results for the second quarter ended June 30, 2025 and providing a corporate update. The filing indicates the press release is included as Exhibit 99.1 and also includes the Cover Page Interactive Data File as Exhibit 104. The registrant is identified as an emerging growth company and has elected not to use the extended transition period for new or revised accounting standards.
The 8-K text itself does not present the numerical results or additional operational details; those items are contained in the referenced press release furnished as an exhibit.
Annovis Bio, Inc. (NYSE: ANVS) filed a Form 8-K reporting the outcome of its 2025 virtual Annual Meeting held on 17 June 2025.
Quorum: 11,588,981 shares (59.47% of shares outstanding).
Proposal 1 – Election of Directors (one-year terms):
- Maria Maccecchini – 4,216,112 FOR / 173,438 WITHHELD / 7,199,431 broker non-votes
- Michael Hoffman – 4,182,806 FOR / 206,744 WITHHELD / 7,199,431 broker non-votes
- Claudine Bruck – 4,041,007 FOR / 348,543 WITHHELD / 7,199,431 broker non-votes
- Reid McCarthy – 4,202,391 FOR / 187,159 WITHHELD / 7,199,431 broker non-votes
- Mark White – 3,780,238 FOR / 609,312 WITHHELD / 7,199,431 broker non-votes
Proposal 2 – Ratification of Independent Auditor: Ernst & Young LLP ratified with 11,382,542 FOR, 187,959 AGAINST, 18,480 ABSTAIN.
All proposals passed; no additional matters were presented.
Annovis Bio, Inc. (NYSE: ANVS) filed an 8-K on June 19, 2025 to disclose that the New York Stock Exchange has accepted the company’s previously submitted listing-compliance plan. The plan was required after Annovis fell out of compliance with NYSE continued-listing standards; acceptance removes the immediate risk of delisting and starts a defined remediation timetable. The 8-K furnishes, but does not file, a press release (Exhibit 99.1) announcing the NYSE decision. No financial statements, earnings data or major transactions were included, and the disclosure is made solely under Item 7.01 (Regulation FD) with no impact on historical financial reporting.
Investors should note that, while acceptance is a constructive step, Annovis must still meet the milestones outlined in the compliance plan to regain full compliance. The filing contains no new operational or financial metrics.
Annovis Bio (ANVS) Vice President of Finance Andrew Walsh reported a new acquisition of company shares on Form 4. The transaction details include:
- Acquired 500 shares of Common Stock
- Purchase price: $2.90 per share
- Transaction date: June 16, 2025
- Total transaction value: $1,450
- Ownership type: Direct
Following this transaction, Walsh holds 500 shares directly. The purchase represents an initial position for the executive, as no prior holdings were reported. The transaction was reported within the required two-business-day filing window, with the Form 4 being filed on June 28, 2025. No derivative securities were involved in this transaction.